GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the privately held company’s roster of next-generation vaccines.
https://www.pharmalive.com/wp-content/uploads/2022/01/GSK-Vir-ramping-up-U.S.-output-of-COVID-antibody-drug-Reuters-1-21-22.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-05-31 04:30:532022-05-31 15:29:44GSK to spend up to $3.3 billion on Affinivax to boost vaccines roster
